Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Preferred Stock Liabilities for 3 consecutive years, with $296.9 million as the latest value for Q4 2023.

  • For Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $296.9 million; the TTM value through Dec 2023 reached $296.9 million, changed N/A, while the annual FY2023 figure was $296.9 million, N/A changed from the prior year.
  • Preferred Stock Liabilities hit $296.9 million in Q4 2023 for Cartesian Therapeutics, up from $5.0 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $296.9 million in Q4 2023 and bottomed at $296.9 million in Q4 2023.